DHODH and cancer: Considering that leflunomide and teriflunomide are currently only approved for rheumatological indications [34], our current approach represents a comprehensive way to derive dosing strategies to effectively and safely modulate DHODH with HOSU-53 in the context of cancer utilizing plasma drug levels and DHO, which will benefit other DHODH inhibitor development.